Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Sep 13, 2005
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
The treatment cycle begins with 6 hours of intravenous (IV) hydration followed by an infusion of the anti-cancer drug, Cisplatin. In addition, at the beginning of this treatment, you will begin low-dose Interferon-alpha injections for the entire duration of your participation in this study. The drug, Interferon-alpha, interrupts the division of cancer cells, destroys tumor blood vessels, and slows tumor growth.
Forty-eight hours after the Cisplatin infusion, you will be treated with fever-range thermal therapy (whole-body hyperthermia, or heat). When your core body temperature reaches 104o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Candidate must have biopsy-documented locally advanced or metastatic pancreas cancer
- • Must be able to successfully complete preliminary function tests
- • Must have a good ECOG score
- • Must have two functioning lungs
- Exclusion Criteria:
- • Must not have active metastasis to the brain
- • Must not have poor preliminary function tests
- • Must not have a low ECOG score
- • Must not be taking high-dose corticosteroids
- • Must be psychologically stable
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Joan M Bull, M.D.
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials